Pharmacokinetics of flomoxef in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients undergoing lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment. Issue 2 (February 2023)

• Record Type: Journal Article
• Authors: Hirano, Toshinori; Ohge, Hiroki; Ikawa, Kazuro; Uegami, Shinnosuke; Watadani, Yusuke; Shigemoto, Norifumi; Yoshimura, Kosuke; Kitagawa, Hiroki; Kaiki, Yuki; Morikawa, Norifumi; Takahashi, Shinya
• Is Part Of: Journal of infection and chemotherapy. Volume 29:Issue 2(2023)
• Page Start: 186
• Page End: 192
• Publication Date: 2023-02
• Subjects: Flomoxef -- Abdominal infections -- Antibiotic prophylaxis -- Extended-spectrum beta-lactamase -- Pharmacokinetics -- Pharmacodynamics; AUC area under the drug concentration-time curve -- ESBL extended-spectrum beta-lactamase -- HPLC high-performance liquid chromatography -- MIC minimum inhibitory concentration -- PK/PD pharmacokinetic/pharmacodynamic -- SD standard deviation -- SSI surgical site infection; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2022.10.017
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Introduction: Flomoxef is generally used to treat abdominal infections and as antibiotic prophylaxis during lower gastrointestinal surgery. It is reportedly effective against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and an increasingly valuable alternative to carbapenems. However, its abdominal pharmacokinetics remain unclear. Herein, pharmacokinetic analysis of flomoxef in the abdominal tissue was conducted to simulate dosing regimens for pharmacodynamic target attainment in abdominal sites. Methods: Flomoxef (1 g) was administered intravenously to a patient 30 min before commencing elective lower gastrointestinal surgery. Samples of plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue were collected during surgery. The flomoxef tissue concentrations were measured. Accordingly, non-compartmental and compartmental pharmacokinetic parameters were calculated, and simulations were conducted to evaluate site-specific pharmacodynamic target values. Results: Overall, 41 plasma samples, 34 peritoneal fluid samples, 38 peritoneum samples, and 41 subcutaneous adipose samples from 10 patients were collected. The mean peritoneal fluid-to-plasma ratio in the areas under the drug concentration-time curve was 0.68, the mean peritoneum-to-plasma ratio was 0.40, and the mean subcutaneous adipose tissue-to-plasma was 0.16. The simulation based on these results showed the dosing regimens (q8h [3 g/day] and q6h [4 g/day]) achieved the bactericidal effect (% T > minimum inhibitory concentration [MIC] = 40%) in all tissues at an MIC of 1 mg/L. Conclusions: We elucidated the pharmacokinetics of flomoxef and simulated pharmacodynamics target attainment in the abdominal tissue. This study provides evidence concerning the use of optimal dosing regimens for treating abdominal infection caused by strains like ESBL-producing bacteria.